Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo ...

Late last week, President Donald Trump sent letters to 17 pharmaceutical companies pressing them to deliver on his May ...

Regeneron, Sanofi say the NOTUS trial met its primary endpoint with overwhelming efficacy. The companies plan to submit the data to the FDA by the end of the year. Live Sunday: Matt Maley’s ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On July 2, the US FDA) granted accelerate approval to Regeneron ...

Today, Regeneron will showcase more from the same study, which featured patients with relapsed/refractory follicular lymphoma (FL). Odronextamab spurred an 82% ORR, with 75% of those patients ...

As we have previously reported, Regeneron’s BPCIA case against Mylan regarding Mylan’s proposed aflibercept biosimilar is proceeding on an expedited schedule, with a two-week trial scheduled ...